Superficial Basal Cell Carcinoma Clinical Trial
Official title:
A Multicenter, Phase III, Randomised Study of Photodynamic Therapy With Metvix Cream 160 mg/g in Comparison With Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma
The purpose of this study is to compare the efficacy of Photodynamic Therapy (PDT) with
methyl aminolevulinate (MAL) cream to cryotherapy, in treatment of patients with primary
superficial basal cell carcinoma.
Secondary objectives are to compare cosmetic outcome and tolerability (adverse events) in
these patients, 3 months after treatment. In addition the recurrence rates in the two
treatment groups will be compared up to five years after treatment.
BCC is a highly frequent skin malignancy, and accounts for approximately 75% of all
non-melanoma skin cancers. It is the most common malignant tumour of any organ, mostly
affecting head and neck (84%) in fair-skinned people. Several non-pharmacological treatment
modalities are used for BCC, including excision surgery, Moh's surgery, radiation,
curettage/electrodesiccation and cryotherapy. The treatment used depends on the type, size,
depth and localisation of the BCC lesion.
The use of PDT is attractive for the treatment of BCCs because of its efficiency, mild and
local side effects and excellent cosmetic outcome. Previous clinical experience is promising
and patients with primary BCCs will be included in this prospective, randomised,
comparative, multicenter study to show that Metvix is non-inferior to alternative treatment
with better cosmetic outcome.
The primary end-point will be the number of patients in whom 75% or more of the BCC lesions
have responded completely at 3 months after PDT with Metvix or 3 months after cryotherapy.
Both on-site and independent, blinded response assessments will be analysed. The analysis
based on the results of the independent review board constitutes the primary analysis.
The secondary end-points will be the proportion of patients in whom less than 75% of the BCC
lesions respond completely, number of lesions across patients that show complete response,
evaluation of cosmetic outcome and adverse events 3 months after Metvix PDT or 3 months
after cryotherapy. In addition 12, 24, 36, 48 and 60 months recurrence rates will be
assessed.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04552990 -
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT03573401 -
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
|
Phase 3 | |
| Completed |
NCT03012009 -
Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial
|
N/A | |
| Completed |
NCT02270645 -
Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser
|
N/A | |
| Recruiting |
NCT05381597 -
5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer
|
Phase 2/Phase 3 | |
| Terminated |
NCT00994240 -
Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC
|
N/A | |
| Completed |
NCT00604890 -
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00189306 -
Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream
|
Phase 3 | |
| Recruiting |
NCT05157763 -
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04744935 -
Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma
|
N/A | |
| Completed |
NCT05628714 -
A Patient Decision Aid for Patients With Superficial Basal Cell Carcinoma
|
||
| Completed |
NCT00432185 -
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
|
Phase 2 | |
| Recruiting |
NCT01491711 -
Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate
|
Phase 4 | |
| Completed |
NCT04470726 -
Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01325688 -
PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities
|
Phase 2 | |
| Recruiting |
NCT05713760 -
Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults
|
Phase 2 |